Full Name
Minetta C. Liu
Professional Designations
MD
Job Title
Chief Medical Officer, Oncology and Early Cancer Detection
Company
Natera
Speaker Bio
Dr. Minetta Liu, M.D. joined Natera in June 2022 as Chief Medical Officer (CMO) of Oncology. In this role, Dr. Liu sets the direction for the company’s clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types and indications.
Prior to her transition to industry, Dr. Liu served as Professor and Research Chair in the Department of Oncology at Mayo Clinic in Rochester, MN. In her ten years at Mayo Clinic, she held a secondary appointment in the Department of Laboratory Medicine and Pathology, served as Co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine, and established the first Precision Oncology Clinic.
Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefit and outcomes for patients with solid tumors. She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium.
Dr. Liu received her B.A. from Princeton University and her M.D. from Jefferson Medical College. She completed her internal medicine residency and hematology/oncology fellowship at Georgetown University Medical Center.
Prior to her transition to industry, Dr. Liu served as Professor and Research Chair in the Department of Oncology at Mayo Clinic in Rochester, MN. In her ten years at Mayo Clinic, she held a secondary appointment in the Department of Laboratory Medicine and Pathology, served as Co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine, and established the first Precision Oncology Clinic.
Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefit and outcomes for patients with solid tumors. She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium.
Dr. Liu received her B.A. from Princeton University and her M.D. from Jefferson Medical College. She completed her internal medicine residency and hematology/oncology fellowship at Georgetown University Medical Center.
Speaking At
